Global Compounding Chemotherapy Market Research Report—Forecast till 2027

$4,450$6,250

As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027.

Clear

Description

Global Compounding Chemotherapy Market Research Report—Forecast till 2027

Market Dynamics
As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027. The global market growth is driven by the surged incidences of cancer, increasing expenditure on medicine & science and reimbursements, and increased health benefits. Further, the Compounding chemotherapy market is attributed to the emerging technical advancements, innovations, and strategies to cater to the demands of clinicians.
The global Compounding Chemotherapy Market is expected to witness substantial market growth owing to the highest market contribution in 2019. The rising opioid scarcity is predicted to increase the demand for compounding chemotherapy globally for compounding chemotherapy. The growth of the market is driven by the benefits of easy-to-use medicines, allowing alternative dosage types to access expired medicines, and making medicines allergen safe. Additionally, hospitals and other healthcare providers are allowing customers to purchase medications that are compounded.

Market Segmentation
Global Compounding Chemotherapy Market has been classified in terms of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application.
Global Compounding Chemotherapy Market in terms of the dose has been bifurcated into chemotherapeutic and non-chemotherapeutics. The global compounding chemotherapy market, by compounding type, has been classified into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). The PDA segment is evaluated to register a fastest growth rate during the forecast period. Based on the delivery method, the global market has been divided into gravimetric automated compounding devices (weight-based) and volumetric automated compounding devices (volume-based).
Based on the global compounding chemotherapy market, has been bifurcated into sterile and non-sterile. The sterile is expected to lead the market owing to the largest share of 56.0% in 2019.

Regional Analysis
Region-specific analysis of Global Compounding Chemotherapy Market, based on region, has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market owing to the surge in cancer patients, an increase in health care rates, and the growing requirement for treatment with chemotherapy in the area. The regional market has been classified into North America and Latin America, with the North American market further divided into the US and Canada.
The European compounding chemotherapy market has been classified into Western Europe and Eastern Europe. The Western Europe compounding chemotherapy market is spread across Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The regional market has been driven by the government-based research program aimed at curing the rising number of cancer cases and increased health spending pushes the growth of the regional chemotherapy market.

Major Players
The Key Players in the Global Compounding Chemotherapy Market include Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 21

2.2 SCOPE OF THE STUDY 21

2.3 RESEARCH OBJECTIVE 21

2.4 MARKET STRUCTURE 22

2.5 ASSUMPTIONS & LIMITATIONS 23

3 RESEARCH METHODOLOGY
3.1 DATA MINING 24

3.2 SECONDARY RESEARCH 25

3.3 PRIMARY RESEARCH 26

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 27

3.5 FORECASTING TECHNIQUES 28

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 29

3.6.1 BOTTOM-UP APPROACH 30

3.6.2 TOP-DOWN APPROACH 30

3.7 DATA TRIANGULATION 31

3.8 VALIDATION 31

4 MARKET DYNAMICS
4.1 OVERVIEW 32

4.2 DRIVERS 33

4.2.1 TECHNOLOGICAL DEVELOPMENTS AND GROUND-BREAKING TECHNIQUES 33

4.2.2 INCREASE IN DRUGS SHORTAGE COMPRISING CANCER MEDICINES 34

4.2.3 RISE IN AWARENESS AND ADAPTATION OF NEW TECHNOLOGIES AMONG CANCER HOSPITALS 34

4.2.4 RISING PREVALENCE OF CANCER PATIENTS 34

4.3 RESTRAINTS 36

4.3.1 DEARTH OF PRACTICED PHARMACISTS AND LAB TECHNICIANS 36

4.4 OPPORTUNITIES 36

4.4.1 NEW PRODUCT INNOVATIONS 36

4.4.2 RISE IN PARTNERSHIPS & COLLABORATIONS 36

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 37

5.1.1 R&D AND DESIGNING 37

5.1.2 MANUFACTURING 38

5.1.3 DISTRIBUTION & SALES 38

5.1.4 POST SALES SERVICES 38

5.2 PORTER’S FIVE FORCES MODEL 38

5.2.1 BARGAINING POWER OF SUPPLIERS 39

5.2.2 BARGAINING POWER OF BUYERS 39

5.2.3 THREAT OF NEW ENTRANTS 39

5.2.4 THREAT OF SUBSTITUTES 40

5.2.5 INTENSITY OF RIVALRY 40

5.3 COVID-19 IMPACT ANALYSIS 40

5.3.1 IMPACT ON SUPPLY CHAIN 41

5.3.2 IMPACT ON PRODUCTION 41

5.3.3 IMPACT ON REGIONS 41

5.3.4 DEMAND-SUPPLY GAP ANALYSIS 41

5.4 LIST OF POTENTIAL CUSTOMERS 42

6 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE
6.1 OVERVIEW 45

6.2 CHEMOTHERAPEUTIC 46

6.3 NON-CHEMOTHERAPEUTICS 46

7 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE
7.1 OVERVIEW 47

7.2 PHARMACEUTICAL INGREDIENT ALTERATION (PIA) 48

7.3 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM) 49

7.4 PHARMACEUTICAL DOSAGE ALTERATION (PDA) 50

8 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD
8.1 OVERVIEW 51

8.2 GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE (WEIGHT-BASED) 52

8.3 VOLUMETRIC AUTOMATED COMPOUNDING DEVICE (VOLUME-BASED) 53

9 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY
9.1 OVERVIEW 54

9.2 STERILE 55

9.3 NON-STERILE 56

10 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY
10.1 OVERVIEW 57

10.2 WITH ROBOTIC ARMS 58

10.3 WITHOUT ROBOTIC ARMS 59

11 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE
11.1 OVERVIEW 60

11.2 PHARMODUCT 61

11.3 EQUASHIELD PRO 61

11.4 MEDIMIX 61

11.5 INTEGRA 61

11.6 OTHERS 61

12 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION
12.1 OVERVIEW 62

12.2 BREAST CANCER 63

12.3 BLOOD CANCER 64

12.4 PROSTATE CANCER 65

12.5 GASTROINTESTINAL CANCER 66

12.6 RESPIRATORY/LUNG CANCER 66

12.7 OTHERS 67

13 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY REGION
13.1 OVERVIEW 68

13.2 AMERICAS 69

13.2.1 NORTH AMERICA 73

13.2.1.1 US 76

13.2.1.2 CANADA 79

13.2.2 LATIN AMERICA 82

13.2.2.1 BRAZIL 85

13.2.2.2 REST OF LATIN AMERICA 88

13.3 EUROPE 92

13.3.1 WESTERN EUROPE 96

13.3.1.1 GERMANY 99

13.3.1.2 FRANCE 102

13.3.1.3 UK 105

13.3.1.4 ITALY 108

13.3.1.5 SPAIN 111

13.3.1.6 REST OF WESTERN EUROPE 114

13.3.2 EASTERN EUROPE 117

13.4 ASIA-PACIFIC 121

13.4.1 CHINA 125

13.4.2 JAPAN 127

13.4.3 INDIA 130

13.4.4 AUSTRALIA 133

13.4.5 SOUTH KOREA 136

13.4.6 REST OF ASIA-PACIFIC 139

13.5 MIDDLE EAST & AFRICA 142

13.5.1 MIDDLE EAST 145

13.5.2 AFRICA 148

14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW 151

14.2 COMPETITOR DASHBOARD 152

14.3 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 153

14.4 MARKET SHARE ANALYSIS 153

14.5 COMPETITIVE BENCHMARKING 154

14.6 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 155

14.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 156

14.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 156

14.8.1 ACQUISITION 156

14.8.2 COLLABORATION 156

14.8.3 PARTNERSHIP 157

14.8.4 COLLABORATION 157

15 COMPANY PROFILE
15.1 B. BRAUN MELSUNGEN AG 158

15.1.1 COMPANY OVERVIEW 158

15.1.2 FINANCIAL OVERVIEW 158

15.1.3 PRODUCTS/SERVICES OFFERED 159

15.1.4 KEY DEVELOPMENTS 159

15.1.5 SWOT ANALYSIS 160

15.1.6 KEY STRATEGIES 160

15.2 PFIZER INC. 161

15.2.1 COMPANY OVERVIEW 161

15.2.2 FINANCIAL OVERVIEW 161

15.2.3 PRODUCTS/SERVICES OFFERED 162

15.2.4 KEY DEVELOPMENTS 162

15.2.5 SWOT ANALYSIS 162

15.2.6 KEY STRATEGIES 163

15.3 BAXTER 164

15.3.1 COMPANY OVERVIEW 164

15.3.2 FINANCIAL OVERVIEW 164

15.3.3 PRODUCTS/SERVICES OFFERED 165

15.3.4 KEY DEVELOPMENTS 165

15.3.5 SWOT ANALYSIS 165

15.3.6 KEY STRATEGIES 166

15.4 GRIFOLS, S.A. 167

15.4.1 COMPANY OVERVIEW 167

15.4.2 FINANCIAL OVERVIEW 167

15.4.3 PRODUCTS/SERVICES OFFERED 168

15.4.4 KEY DEVELOPMENTS 168

15.4.5 SWOT ANALYSIS 168

15.4.6 KEY STRATEGIES 169

15.5 THE METRIX COMPANY 170

15.5.1 COMPANY OVERVIEW 170

15.5.2 FINANCIAL OVERVIEW 170

15.5.3 PRODUCTS/SERVICES OFFERED 170

15.5.4 KEY DEVELOPMENTS 170

15.5.5 SWOT ANALYSIS 171

15.5.6 KEY STRATEGIES 171

15.6 ADDED PHARMA 172

15.6.1 COMPANY OVERVIEW 172

15.6.2 FINANCIAL OVERVIEW 172

15.6.3 PRODUCTS/SERVICES OFFERED 172

15.6.4 KEY DEVELOPMENTS 173

15.6.5 SWOT ANALYSIS 173

15.6.6 KEY STRATEGIES 173

15.7 EQUASHIELD 174

15.7.1 COMPANY OVERVIEW 174

15.7.2 FINANCIAL OVERVIEW 174

15.7.3 PRODUCTS/SERVICES OFFERED 174

15.7.4 KEY DEVELOPMENTS 174

15.7.5 SWOT ANALYSIS 175

15.7.6 KEY STRATEGIES 175

15.8 MILLERS PHARMACY 176

15.8.1 COMPANY OVERVIEW 176

15.8.2 FINANCIAL OVERVIEW 176

15.8.3 PRODUCTS/SERVICES OFFERED 176

15.8.4 KEY DEVELOPMENTS 176

15.8.5 SWOT ANALYSIS 177

15.8.6 KEY STRATEGIES 177

15.9 COMECER S.P.A. 178

15.9.1 COMPANY OVERVIEW 178

15.9.2 FINANCIAL OVERVIEW 178

15.9.3 PRODUCTS/SERVICES OFFERED 178

15.9.4 SWOT ANALYSIS 179

15.9.5 KEY STRATEGIES 179

15.10 OMNICELL 180

15.10.1 COMPANY OVERVIEW 180

15.10.2 FINANCIAL OVERVIEW 180

15.10.3 PRODUCTS/SERVICES OFFERED 180

15.10.4 SWOT ANALYSIS 181

15.10.5 KEY STRATEGIES 181

15.11 ICON GROUP 182

15.11.1 COMPANY OVERVIEW 182

15.11.2 FINANCIAL OVERVIEW 182

15.11.3 PRODUCTS/SERVICES OFFERED 182

15.11.4 KEY DEVELOPMENTS 183

15.11.5 SWOT ANALYSIS 184

15.11.6 KEY STRATEGIES 184

15.12 DEDALUS GROUP 185

15.12.1 COMPANY OVERVIEW 185

15.12.2 FINANCIAL OVERVIEW 185

15.12.3 PRODUCTS/SERVICES OFFERED 185

15.12.4 KEY DEVELOPMENTS 185

15.12.5 SWOT ANALYSIS 186

15.12.6 KEY STRATEGIES 186

15.13 ARXIUM 187

15.13.1 COMPANY OVERVIEW 187

15.13.2 FINANCIAL OVERVIEW 187

15.13.3 PRODUCTS/SERVICES OFFERED 187

15.13.4 KEY DEVELOPMENTS 187

15.13.5 SWOT ANALYSIS 188

15.13.6 KEY STRATEGIES 188

15.14 STERILINE S.R.L. 189

15.14.1 COMPANY OVERVIEW 189

15.14.2 FINANCIAL OVERVIEW 189

15.14.3 PRODUCTS/SERVICES OFFERED 189

15.14.4 KEY DEVELOPMENTS 189

15.14.5 SWOT ANALYSIS 190

15.14.6 KEY STRATEGIES 190

15.15 LOCCIONI 191

15.15.1 COMPANY OVERVIEW 191

15.15.2 PRODUCTS/SERVICES OFFERED 191

15.15.3 KEY DEVELOPMENTS 191

15.15.4 SWOT ANALYSIS 192

15.15.5 KEY STRATEGIES 192

16 APPENDIX
16.1 REFERENCES 193

16.2 RELATED REPORTS 193

RSS
Follow by Email